Search | Clinical Trials Finder

Conditions: Migraine
Interventions: topical intraoral ketoprofen gel, Placebo Gel; Drug · Other
Lead sponsor: Behar, Caren, M.D.; Individual
Eligibility: 18 Years to 75 Years
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Valhalla, New York

Conditions: Anorexia Nervosa, Osteopenia, Osteoporosis, Eating Disorders
Interventions: Recombinant Human Growth Hormone, Placebo for Recombinant Human Growth Hormone; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 14 Years to 45 Years · Female only
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Metastatic Breast Cancer
Interventions: ABT-869, paclitaxel, Placebo for ABT-869; Drug
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 18 Years and older · Female only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 2
States / cities: San Francisco, California • Harvey, Illinois

Conditions: Migraine
Interventions: 91-day Levonorgestrel Oral Contraceptive, Placebo; Drug
Lead sponsor: Duramed Research; Industry
Eligibility: 18 Years to 34 Years · Female only
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 22
States / cities: La Mesa, California • San Diego, California • San Francisco, California + 18 more

Conditions: Diarrhea, Gastroenteritis
Interventions: Zinc Sulfate, Placebo oral capsule; Drug
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 6 Months to 6 Years
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Major Depressive Diorder, Early Life Trauma
Interventions: Lumateperone 42 mg, Placebo; Drug · Other
Lead sponsor: University of Texas at Austin; Other
Eligibility: 21 Years to 70 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Head and Neck Cancer
Interventions: Tadalafil, Placebo; Drug · Other
Lead sponsor: Donald T. Weed; Other
Eligibility: 18 Years to 120 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Polymyositis, Dermatomyositis
Interventions: KZR-616, Placebo; Drug
Lead sponsor: Kezar Life Sciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 12
States / cities: Beverly Hills, California • Orange, California • Miami, Florida + 9 more

Conditions: Juvenile Neuronal Ceroid Lipofuscinosis
Interventions: Mycophenolate mofetil, Liquid Placebo; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 6 Years to 25 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Overactive Bladder
Interventions: Mirabegron 50 MG, Posterior Tibial Nerve Stimulation (PTNS); Drug · Device
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older · Female only
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Constipation, Bowel Dysfunction
Interventions: alvimopan, placebo; Drug
Lead sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years and older
Enrollment: 233 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 69
States / cities: Tucson, Arizona • Hot Springs, Arkansas • Duarte, California + 58 more

Conditions: Breast Adenocarcinoma, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7
Interventions: Multi-epitope HER2 Peptide Vaccine TPIV100, Pertuzumab, Placebo Administration, Sargramostim, Trastuzumab, Trastuzumab Emtansine; Biological · Other
Lead sponsor: Academic and Community Cancer Research United; Other
Eligibility: 18 Years and older · Female only
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 30
States / cities: Scottsdale, Arizona • Tucson, Arizona • Yuma, Arizona + 26 more

Conditions: Spinal Cord Injuries, Myelopathy
Interventions: Istradefylline, low oxygen therapy; Drug · Device
Lead sponsor: Randy Trumbower, PT, PhD; Other
Eligibility: 18 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Major Depressive Disorder
Interventions: Escitalopram Pill, Placebo, Levomilnacipran Pill; Drug · Other
Lead sponsor: Howard Aizenstein; Other
Eligibility: 60 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Pulmonary Hypertension
Interventions: sitaxsentan sodium; Drug
Lead sponsor: Encysive Pharmaceuticals; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Atopic Dermatitis
Interventions: S. hominis A 9 Product, Placebo; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 80 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Herpes Labialis
Interventions: iontophoretic acyclovir; Device
Lead sponsor: Transport Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,800 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 26
States / cities: Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 22 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Semaglutide (1 Mg Dose), Placebo; Drug
Lead sponsor: Geisinger Clinic; Other
Eligibility: 18 Years to 75 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Danville, Pennsylvania

Conditions: Peanut Allergy
Interventions: AR101; Biological
Lead sponsor: Aimmune Therapeutics, Inc.; Industry
Eligibility: 4 Years to 55 Years
Enrollment: 388 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 47
States / cities: Tucson, Arizona • Little Rock, Arkansas • Mission Viejo, California + 39 more

Conditions: Healthy Volunteers, Primary Sclerosing Cholangitis
Interventions: TAK-781, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 68 Years
Enrollment: 134 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Prostate Cancer
Interventions: bicalutamide, eflornithine, oral eflornithine placebo, oral bicalutamide placebo; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older · Male only
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Mitochondrial Diseases, Drug Resistant Epilepsy, Leigh Disease, Leigh Syndrome, Mitochondrial Encephalopathy (MELAS), Pontocerebellar Hypoplasia Type 6 (PCH6), Alpers Disease, Alpers Syndrome
Interventions: Vatiquinone, Placebo; Drug · Other
Lead sponsor: PTC Therapeutics; Industry
Eligibility: Up to 20 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 12
States / cities: San Diego, California • Stanford, California • New Haven, Connecticut + 7 more

Conditions: Fecal Incontinence
Interventions: Loperamide, Placebo, Anal exercises with biofeedback, Usual Care; Drug · Behavioral
Lead sponsor: NICHD Pelvic Floor Disorders Network; Network
Eligibility: 18 Years and older · Female only
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 9
States / cities: Birmingham, Alabama • La Jolla, California • San Diego, California + 6 more

Conditions: Healthy Study Participants
Interventions: UCB0599, Esomeprazole, Placebo; Drug · Other
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 73 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Glendale, California

Search by objective public record fields.

Topical Intra-Oral Ketoprofen for Migraine Prevention

Effect of Growth Hormone on Bone Metabolism in Anorexia Nervosa

Phase 2 Study of ABT-869 in Combination With Paclitaxel Versus Paclitaxel Alone to Treat Metastatic Breast Cancer

A Multicenter Study to Evaluate the Efficacy of a 91-Day Extended Cycle Oral Contraceptive for Menstrually-Related Migraine Headaches

Oral Zinc for the Treatment of Acute Diarrhea in US Children

Neurocircuitry Mechanisms and Efficacy of Lumateperone as Adjunctive Therapy for Major Depressive Disorder and History of Early Life Abuse

Tadalafil in Treating Patients Undergoing Surgery for Cancer of the Oral Cavity or Oropharynx

A Phase 2 Study of KZR-616 to Evaluate Safety and Efficacy in Patients With Active Polymyositis or Dermatomyositis

Cellcept for Treatment of Juvenile Neuronal Ceroid Lipofuscinosis

Posterior Tibial Nerve Stimulation (PTNS) Plus Mirabegron to Treat Refractory OAB Symptoms (PTNS-M Study)

Study Of Alvimopan Drug For Treatment Of Constipation Due To Prescription Pain Medication

TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery

Combining Low Oxygen Therapy and an Adenosine A2a Receptor Antagonist to Improve Functional Mobility After Spinal Cord Injury

Neural Mechanisms of Monoaminergic Engagement in Late-life Depression Treatment Response (NEMO)

Safety and Efficacy Study of Sitaxentan Sodium (Thelin™) in Patients With Pulmonary Arterial Hypertension

Targeted Investigation of Microbiome Elimination

Iontophoretic Application of Acyclovir Cream to Treat Recurrent Herpes Labialis

Treatment of GLP-1 for Diabetic Bariatric Patients

PALISADE Follow-on Study (ARC004)

A Study of TAK-781 in Healthy Volunteers and in Participants With Non-Cirrhotic Primary Sclerosing Cholangitis (PSC)

Neoadjuvant Eflornithine and Bicalutamide Compared With Eflornithine Alone, Bicalutamide Alone, and No Neoadjuvant Therapy in Treating Patients With Localized Prostate Cancer Undergoing Brachytherapy or Radical Prostatectomy

A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy

Controlling Anal Incontinence by Performing Anal Exercises With Biofeedback or Loperamide (CAPABLe)

A Study to Test Bioavailability of of 2 New Formulations of UCB0599 in Healthy Participants in Part A and to Test Safety, Tolerability, and Pharmacokinetic (PK) of UCB0599 in Healthy Japanese and Chinese Participants in Part B